Richard Skaife 🍄

Proud moment @VICE covered our recent @MicrodoseHQ #PsyCap in this article vice.com/en/article/m7a…

@levelsio @marclou That explains it.

@marclou Hotel ACs at 18°C are often hacked so they show 3-5C lower than it is They generally IME do not hit below 22°C in US and EU Middle East and Asia are fine

My Resting Heart Rate is up 10% since I left my Eight Sleep mattress. AC is blasting at 18° in the hotel room, but I still feel too hot. It's very hard to maintain a healthy routine while traveling.

@charliewrich Perfect moment to say “ don’t you know who I am “

Working on a flight Guy next to me keeps reading as I type out unhinged posts from multiple accounts Not even worth trying to explain it to him

@TheJerzWay If you make it over to Malta, delighted to show you round and do any helpful intros to govt. It’s a refreshing way they look at enterprise.

@tokenrichard Wonderful!

Malta non-dom status explained in 60 seconds: You become tax resident in Malta. You keep your foreign income offshore. You pay zero. Bring money into Malta? 15% flat. Minimum tax: €5,000/year. That's it. That's the whole play. 🧵 Here's who this is perfect for...

@alc2022 Consumer biotech and the true personalisation of it ( or with a Z if you’re American ) is my big focus. Launching a Personalized Peptides AI engine in next few weeks. 6 years deploying capital into psychedlics and that is just about to get serious too.

The last time I spent years studying something nobody cared about, I bought Palantir at $7. Biology is where I am now. AI<>Peptides is the next big thing. Two decades of asymmetric returns ahead. Here's the map.

@Barney_H_Y Happy to intro you to the group we use for this ….they have a team who handle funds and similar. DM me if needed.

What do people use to send large transfers (angel investments, etc) and not have to fight through the dumbest anti fraud checks possible? Used to use Rev but now almost unusable.

@nic_carter @TXMCtrades Likewise and no drinking and take magnesium glycinate ( and having the best sleeps from it )

@TXMCtrades - you quit weed or drinking regularly - you started tirzepatide - you started taking glycine/magnesium/melatonin whatever it is, going from dreamless sleep to dreams is typically a good thing. you are getting more REM

I didn't dream for many years. Figured it was an ability I'd lost (is that a thing?). But in the past couple months they've suddenly roared back with a vengeance and they're SO vivid. Every night like a mfer. Images and feelings that linger all day. Sup with that?

@bunq Ahh just it said all users which it’s not. Sadly.

@tokenrichard Hey Richard 👋 Baskets are currently available in all countries where bunq Stocks is supported. You can find all the details here: help.bunq.com/articles/start…

Don't have time to research hundreds of stocks? With Baskets, you can create a portfolio of stocks and ETFs in seconds, based on what you care about. Start investing from just €10 today. Baskets will be available to all bunq users in the coming weeks!

@RobinLauber_ @C_Angermayer @ataibeckley Even with today’s early rally - still remains a massively underpriced asset. Invested in 2020 and not sold a share.

@POTUS @C_Angermayer We've been in this space for a while. Backed @AtaiBeckley ($ATAI) early — the leading psychedelic platform. For a long time this felt like an industry that was always "almost ready." That's changing now. What's your read — how fast does capital reprice this?

The FDA just got ordered to fast-track psychedelic therapy. This is bigger than most people realise. A thread 🧵

Both April 16 and 19 are special days in the psychedelic calendar. Looks like we can add 18 to that list now.

@C_Angermayer It’s been a long time coming.

Today’s Presidential Executive Order on #psychedelics marks a major milestone in the history of these valuable substances. It corrects a fundamental mistake made in 1970, when President Nixon established the Controlled Substances Act (CSA) and classified psychedelics as Schedule I substances - a designation that had no basis. For largely political reasons, these highly promising compounds were pushed out of the medical realm and into illegality. Now, they are coming back - with force. The executive order is directing the Food and Drug Administration (FDA), the Drug Enforcement Administration (DEA), the Department of Justice and other federal agencies to reduce the red tape and restrictions that have long stymied researchers and biotech companies in the field. As a result, I expect drug approval processes to accelerate and become less costly. I am very proud that @ataibeckley is at the forefront of this field, with one of the broadest pipelines in psychedelics, including clinical programs focused on DMT, 5-MeO-DMT, R-MDMA and – as previously disclosed - ibogaine and additional novel, discovery compounds in various stages of preclinical development. Since I founded AtaiBeckley in 2017, and seed-funded @COMPASSPathway that same year, these two companies have raised more than $1.5 billion to advance clinical research and development of psychedelic therapies. As access to capital was limited early on - since most investors dismissed the idea as crazy - I invested over $100 million of my own capital and have never sold a single $ATAI share (nor do I intend to). The public sentiment around psychedelics as FDA-regulated drugs has gone from “this is a crazy idea that will ruin your career” to being on the verge of what the market anticipates will be the first regulatory approval of a psychedelic with COMP360… all in less than a decade. What a journey. But we are still only at the beginning. I strongly believe the world will benefit from the full spectrum of psychedelic compounds that demonstrate medical and commercial value. I also believe that delivery mechanisms and treatment duration are critical, as these therapies must fit within the commercial realities and infrastructure of the U.S. and global healthcare systems. That conviction is exactly why AtaiBeckley has built such a broad and diversified pipeline with a focus on short-acting psychedelics: x.com/C_Angermayer/s… Once approved, I expect physicians will determine which treatments are best suited to specific patient profiles. Over time, better data and real-world evidence will significantly improve this matching - delivering the right FDA-approved treatment to the right patient. This level of presidential attention also reinforces another long-held belief of mine: the support – and potential use - for psychedelic therapies is far larger and broader than most people have historically assumed. Take once more AtaiBeckley as an example. Most analysts currently model compounds like BPL-003 and VLS-01 primarily within treatment-resistant depression (TRD) - patients who have already failed at least two antidepressant treatments. But my own personal view (and ultimate vision) would be to progress to these treatments sooner, especially when existing treatments often have limited efficacy and significant side effects. Given the favorable safety profiles and promising efficacy of psychedelics we are seeing in the clinical trials run to date, and based on my own extensive discussions with therapists who have worked with these compounds, I personally believe psychedelic therapies have the potential to become first-line treatments - and, over time, even potentially play a role in prevention. Thank you, @realDonaldTrump, for today’s important signal of support, and @joerogan for driving it! Most importantly, thank you to everyone working behind the scenes to make this possible today - and to the fellow drug developers advancing these therapies. This has been, and will continue to be, a truly collaborative effort. You can all be proud of the meaningful difference you are about to make for the millions of patients in need.

@FutureJurvetson @gjurvetson As a long term supporter ( and investor ) many thanks. Let’s hope Europe follows the lead.

🏛️ Historic moment in the Oval Office just now for advancing psychedelic cures for the mental health crisis. “The Prohibition on Psychedelics is now over.” — Bryan Hubbard Funniest quip: “Ibogaine, can I get some?” — POTUS With a chorus of support from leaders I photographed here, L to R: heads of NIDA, NIH, (Joe Rogan), HHS, White House Advisor Calley Means, FDA, and Genevieve who had been working on this for years. Expect three accelerated programs for FDA approval next week, VA studies and Federal funding, and a hope for CMS reimbursement by end of year. Full text: whitehouse.gov/presidential-a…

BREAKING: President Trump announces historic reforms to accelerate access to new medical research and treatments based on psychedelic drugs. Trump will sign an executive order directing the FDA to expedite their review of certain psychedelics already designated as breakthrough therapy drugs.

@paulbz I like the high quality adverts on IG - maybe they could just launch a service with just ads and cut out the rest.

I left Facebook in 2016 and Instagram in 2024. I miss nothing.

Phone started going crazy whilst I was on a call with @djlisalashes chatting about Ibogaine and the PsyMed world with this news. cbsnews.com/news/psychedel…

@BowTiedMara Great read / summary

For now, the gold rush for Argentina's citizenship is on pause. And it is not the only route that's frozen. Decree 366/2025 from May last year moved naturalization processing from the federal courts to Migraciones (DNM). Almost a year later, the kiosko at Migraciones still does not exist. No new applications have been processed since the decree, and the only cases moving are the grandfathered ones still sitting on judges' desks from before the handover. So as of right now: no working Citizenship by Investment tender, no functioning naturalization pipeline, and no clear timeline for either. The door to the Argentine passport is technically open. Practically, nobody is at the desk:

@KiesowPaul Congrats - looking forward to following 🥸

It's a gargantuan milestone for everyone on this April day in 2026. A provisional U.S. Patent with the outrageous sounding title, "METHODS AND COMPOSITIONS FOR TREATING AGE-RELATED DECLINE" has been filed, with Knobbe Martens LLC, the global powerhouse IP medical and biotech law firm, representing us. 'Let that sink in,' as someone famous once said.

@ollieforsyth ⛓️

One emoji which sums up Forbes 30 under 30 Go!

@TurnerNovak And naturally also the true owner of the title of the first one person billion dollar start up.

JUST IN: Following an 18-month investigation, the New York Times has identified Russ Hanneman as Satoshi Nakamoto, the anonymous creator of Bitcoin.